Date: 2017-07-13
Type of information: Licensing agreement
Compound: Eladynos®/Tymlos® (abaloparatide)
Company: Radius Health (USA - MA) Teijin (Japan)
Therapeutic area: Bone diseases
Type agreement: development - licensing
Action mechanism:
- peptide. Abaloparatide-SC is a novel 34–amino acid peptide created to be a potent and selective activator of the parathyroid hormonereceptor type 1 (PTHR1) signaling pathway.
Disease: osteoporosis
Details:
- • On July 13, 2017, Radius Health announced that it has entered into a license and development agreement with Teijin Limited in Japan for abaloparatide-SC. Teijin is developing abaloparatide-SC in Japan under an agreement with Ipsen Pharma and has initiated a phase 3 trial in Japanese patients with osteoporosis.
- The collaboration agreement provides Teijin with the right to manufacture abaloparatide-SC for commercial supply in Japan, as well as the right to reference Radius' NDA and MAA and regulatory data to support its marketing application in Japan and to use Radius intellectual property, and provides Radius with an option to negotiate a co-promotion agreement for abaloparatide-SC in Japan. Radius will also receive upfront and milestone payments and royalties for the rights granted to Teijin. Teijin is conducting and funding its Japanese phase 3 development program and the parties may further collaborate in the future in new indications for the product. Radius maintains full global rights to its development program for abaloparatide-transdermal (abaloparatide-TD), which is not part of the agreement with Teijin.
Financial terms:
Latest news:
Is general: Yes
